The WACC of Oryzon Genomics SA (ORY.MC) is 10.2%.
| Range | Selected | |
| Cost of equity | 8.10% - 13.00% | 10.55% |
| Tax rate | 34.50% - 35.00% | 34.75% |
| Cost of debt | 5.00% - 5.00% | 5.00% |
| WACC | 7.9% - 12.5% | 10.2% |
| Category | Low | High |
| Long-term bond rate | 3.1% | 3.6% |
| Equity market risk premium | 7.4% | 8.4% |
| Adjusted beta | 0.67 | 1.05 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 8.10% | 13.00% |
| Tax rate | 34.50% | 35.00% |
| Debt/Equity ratio | 0.05 | 0.05 |
| Cost of debt | 5.00% | 5.00% |
| After-tax WACC | 7.9% | 12.5% |
| Selected WACC | 10.2% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for ORY.MC:
cost_of_equity (10.55%) = risk_free_rate (3.35%) + equity_risk_premium (7.90%) * adjusted_beta (0.67) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.